Cizzle Biotechnology Holdings PLC Update on Licensing and Partnership Agreement

RNS Number : 8688G

Cizzle Biotechnology Holdings PLC

04 October 2024

 

3 October 2024

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Further Update on Strategic Licensing and Partnership Agreement for North America

Cizzle Biotechnology, the UK based diagnostics developer, today provides a further update on progress with the Company's planned strategic and exclusive licensing partner in the USA, Cizzle Bio Inc ("BIO").

Following the Company's signing of a memorandum of understanding ("MoU") with BIO announced on 2 April 2024 and the 60 day extension to finalise a full and binding license agreement (the "Agreement") announced on 25 July 2024, the Company has continued to support BIO's plans to market the Company's CIZ1B biomarker and to complete the Agreement. The final details of the Agreement are expected to be completed shortly, at which time the Company will make a further announcement.

In the meantime, BIO continues to attract significant clinical interest to build on the recent collaboration with Moffitt Cancer Center, the number one cancer hospital in Florida and the Southeast USA, to test patients with suspicious lung nodules, as announced on 9 September 2024.

Enquiries:

 

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

 

Allenby Capital Limited	[phone]
John Depasquale/George Payne (Corporate Finance)
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

IFC Advisory Limited		[phone]
Tim Metcalfe
Florence Chandler

 

About Cizzle Biotechnology

Cizzle is developing a blood test to help in the early detection of lung cancer. Based on the pioneering work of Professor Coverley and colleagues, at the University of York, on a naturally occurring cell nuclear protein involved in DNA replication called CIZ1, they discovered that a variant called CIZ1B is highly associated with the presence of early-stage cancer. The company has now entered into commercial royalty bearing licensing agreements and collaborations with leading centres of excellence in cancer for the use of its proprietary technology as part of its strategy to bring its non-intrusive, cost-effective blood test to market. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021. 

 

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

About Cizzle Bio Inc

Cizzle Bio Inc, a company registered in Texas USA,  stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDFXLFBZBLZFBE